NEW YORK (GenomeWeb News) – Kindstar Global will validate and implement Advanced Cell Diagnostics' RNAscope technology-based molecular diagnostic assays as part of a partnership the firms announced today.

The firms said that the deal will allow Kindstar to leverage ACD's RNA biomarker analysis platform to offer new cancer diagnostic tests to the 3,300-plus hospitals in Kindstar's network in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.